EnteroBiotix has secured regulatory approval to conduct tests of its microbiome-derived products on patients that build on the firm’s faecal microbial transplant (FMT) science.
More than a quarter of adults aged 50 and over are vitamin D deficient, say researchers, who urge supplement uptake and a mandatory food fortification policy as most effective in tackling deficiencies.
Bacteriophages can have a cascade of effects on the microbiome and change metabolite levels, with implications for therapeutic use, new research suggests.
Global omega-3 player KD Pharma says the new site at Seal Sands will expand its capacity for manufacturing omega-3-based intermediates, especially for those use in producing active pharmaceutical ingredients (APIs).
European microbiome firms are to collaborate to agree pan-EU regulation for microbiome-based therapeutics in efforts to keep pace with advances made in Faecal Microbiota Transplantation (FMT).
OptiBiotix Health continues the profitable drive of its Lactobacillus plantarum (LPLDL) probiotic strain in a license agreement with Nutrilinea for its use as a food supplement ingredient to help reduce high blood pressure.
Individualised nutrition not only helps patients consume more protein and calories, but also improves clinical treatment outcomes and reduces mortality rate, according to a Swiss study of more than 2,000 patients.
Nutrition guidelines must ask the right questions and include a degree of complexity to improve their relevance and quality, according to a research team writing in the BMJ.
With ever-blurring lines between the food and pharmaceutical space, the NutraIngredients team asked experts at our recent Probiota conference how they believe the microbiome space will develop in the future.
Swedish-based Carbiotix continues to build on its gut health testing activities, having closed its latest funding round, bringing the total raised to date at €1m over the past 4 years.
There is no link between dietary intake of minerals and the onset in later life of multiple sclerosis (MS), according to a US study that plays down the role of zinc and iron deficiencies.
Chr. Hansen applies its microbiome expertise in the pharma arena as the firm enters a collaboration with Lonza to produce live biotherapeutic (LBP) products that address a range of gastrointestinal and cardiovascular conditions.
The Norwegian Government is to allow commercial harvesting of Calanus finmarchicus, an ecologically sustainable omega-3 fatty acid source found in huge quantities in the Norwegian Sea.
The European Medicines Agency (EMA) confirms that omega-3 fatty acid medicines are not effective in preventing further cardiovascular problems in patients who have had a heart attack.
